Sanofi SA is primarily active in the pharmaceutical and healthcare industries.

The main competitors of Sanofi SA in the market are Novartis AG, Pfizer Inc., and Merck & Co., Inc.

Sanofi SA, a leading pharmaceutical company, has a rich history and background. Established in 1973, Sanofi SA traces its origins to a merger between Sanofi and Synthélabo, two renowned French pharmaceutical companies. Over the years, Sanofi SA has expanded globally and is now headquartered in Paris, France. With a strong focus on research and development, Sanofi SA strives to deliver innovative medical solutions to improve the health and well-being of individuals worldwide. The company is involved in diverse therapeutic areas, including diabetes, vaccines, rare diseases, cardiovascular diseases, and more. Sanofi SA's commitment to excellence and patient care has solidified its position as a leading player in the pharmaceutical industry.

Sanofi SA, a leading pharmaceutical company, has achieved significant milestones throughout its history. Established in 1973, Sanofi SA has continuously strived for innovation and excellence in the healthcare industry. Some noteworthy achievements include the development of breakthrough medications, such as Plavix and Lantus, that have positively impacted global health. Sanofi SA has also made remarkable strides in areas such as diabetes management, oncology research, and vaccines. The company's commitment to research and development has led to numerous regulatory approvals and successful collaborations with other healthcare organizations. With its strong track record, Sanofi SA continues to revolutionize healthcare and improve patient outcomes globally.

Sanofi SA, a renowned pharmaceutical company, has a significant global presence. The company is primarily present in multiple countries and regions across the world. Some notable countries where Sanofi SA operates prominently include France, the United States, Germany, China, Japan, Brazil, and the United Kingdom. These regions offer Sanofi SA a vast market reach and strategic foothold, allowing the company to deliver its innovative healthcare solutions and medicines to numerous patients worldwide. With its widespread presence, Sanofi SA continues to make a positive impact on healthcare systems globally, addressing the needs of diverse populations and contributing to improved health outcomes.

Sanofi SA represents values of innovation, excellence, and integrity. As a global pharmaceutical company, Sanofi focuses on discovering, developing, and delivering healthcare solutions that enhance people's lives. The company's corporate philosophy centers around patient-centered approaches, scientific expertise, and ethical business practices. Sanofi is committed to addressing unmet medical needs, fostering a culture of diversity and inclusion, and ensuring sustainability in all aspects of its operations. With its dedication to improving global health, Sanofi SA strives to be a trusted partner and a leader in healthcare innovation.

Analysts currently set an average price target of 100,14 EUR for the Sanofi stock (median: 102,00 EUR), implying +33,0 % versus the latest price. The consensus is based on 30 analyst ratings.

Sanofi Циљне цене аналитичара 2026

30 analysts currently rate the Sanofi stock: 19 recommend buying, 10 holding and 1 selling. For 2026, analysts expect Sanofi to generate revenue of 48,55 Млрд EUR and earnings per share of 8,53 EUR.

Sanofi Циљне цене аналитичара 2026

The Sanofi share (SAN.PA) is listed on 15 stock exchanges, including: NASDAQ (SNYNF), XETRA (SNW.DE), Frankfurt (SNW.F), München (SNW.MU), Stuttgart (SNW.SG), Düsseldorf (SNW.DU), Berlin (SNW.BE), Hamburg (SNW.HM).

Sanofi SA is a company headquartered in Paris that manufactures pharmaceutical products for a variety of diseases and medical areas. The company was formed in 2004 from the merger of Sanofi-Synthélabo and Aventis. Sanofi has various divisions, including Vaccines, Specialty Care, Consumer Healthcare, and Generics. The Vaccines division focuses on the development and production of vaccines for the prevention of infectious diseases such as influenza, polio, and meningitis. The Specialty Care division develops and distributes medications for rare diseases such as Fabry's disease, hemophilia, and multiple sclerosis. The Consumer Healthcare division produces over-the-counter drugs, vitamins, and supplements, while the Generics division manufactures generic drugs. Some of Sanofi's most well-known products include Lovenox, Plavix, Actonel, Allegra, and Nasacort. Lovenox is an anticoagulant used for the prevention and treatment of blood clots. Plavix is an antiplatelet medication used for cardiovascular conditions such as stroke and heart attack. Actonel is a bisphosphonate used for the treatment and prevention of osteoporosis. Allegra is an antihistamine used for allergies, while Nasacort is a nasal spray used for allergy treatment. Sanofi also focuses on the development of new medications and has an extensive pipeline of drug candidates in various stages of clinical development. Some of Sanofi's emerging products include Dupilumab for the treatment of atopic dermatitis and asthma, as well as Cablivi for the treatment of thrombotic thrombocytopenic purpura. Sanofi's business model is based on the manufacturing and marketing of pharmaceutical products and vaccines. The company invests significant resources in research and development of new drugs and has a strong presence in key markets worldwide. Sanofi offers a wide range of products in various therapeutic areas and provides a variety of medications for patients with different needs. The company also works closely with regulatory authorities to ensure that its products meet the highest quality standards and meet the needs of patients. Sanofi also has partnerships with other companies in the industry to accelerate the development of new products and prevent the spread of diseases. Overall, Sanofi's business model is focused on the development and marketing of innovative pharmaceutical products and vaccines to improve the well-being of patients worldwide. The company continues to invest in research and development and strives to meet the needs of patients in the fast-paced and constantly evolving world of the healthcare industry.

očekivana prihod od Sanofi je 48,55 Млрд EUR. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od Sanofi je 10,34 Млрд EUR. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Sanofi je trenutno 8,83. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Sanofi.

Odnos cene i prihoda (KUV) za Sanofi je trenutno 1,88. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Sanofi.

Eulpool score kvaliteta za Sanofi je 5/10.

ISIN za Sanofi je FR0000120578. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Sanofi je 920657. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Sanofi je SAN.PA. Simbol tikera se koristi za trgovinu akcijama Sanofi na berzanskom tržištu.

Током протеклих 12 месеци, Sanofi је исплатила дивиденду од 3,92 EUR . Ово одговара приносу од дивиденде од око 5,20 %. За наредних 12 месеци, очекује се да Sanofi исплати дивиденду од 4,33 EUR.

Дивидендна приносна норма од Sanofi износи тренутно 5,20 %.

Sanofi исплаћује дивиденду, која се расподељује у месецима , , , .

Sanofi је исплаћивала дивиденде сваке године у протеклих 26 година.

За наредних 12 месеци, очекују се дивиденде у износу од 4,33 EUR. Ово одговара приносу од дивиденде од 5,83 %.

Sanofi је додељена сектору 'Zdravstvo'.

Да бисте добили последњу дивиденду компаније Sanofi од у износу од 4,12 EUR, требало је да имате акције у портфељу пре ex-дана .

Исплата последње дивиденде извршена је .

У години 2025, Sanofi је исплатила 3,76 EUR као дивиденде.

Дивиденде компаније Sanofi се расподељују у EUR.